Intelligence » Hepatitis B » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Dynavax to introduce new hepatitis B vaccine

Wednesday, November 15, 2017 -- Michael JohnsenHeplisav-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults. read more

KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians

Friday, November 17, 2017 -- by Louis-Marie Yindom, Maimuna Mendy, Christopher Bodimeade, Caroline Chambion, Peter Aka, Hilton C. Whittle, Sarah L. Rowland-Jones, Robert Walton Background Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in low income countries, and incidence is rising rapidly in the developed world with the spread of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infections and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in determining both outcome of initial hepatitis infection and subsequent chronic liver disease and tumour formation. HBV is highly prevalent in The Gambia and the commonest cause of liver disease. The Gambia Liver Cancer Study

HBV: More Screening Needed (CME/CE)

Monday, November 20, 2017 -- (MedPage Today) -- Guidelines aim to close gaps in screening, reduce transmission